0.6723
Precedente Chiudi:
$0.7389
Aprire:
$0.7499
Volume 24 ore:
5.65M
Relative Volume:
1.02
Capitalizzazione di mercato:
$202.84M
Reddito:
$52.29M
Utile/perdita netta:
$-134.84M
Rapporto P/E:
-0.8964
EPS:
-0.75
Flusso di cassa netto:
$-117.11M
1 W Prestazione:
-1.55%
1M Prestazione:
+26.42%
6M Prestazione:
-7.12%
1 anno Prestazione:
-18.57%
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Confronta SGMO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SGMO
Sangamo Therapeutics Inc
|
0.6723 | 222.93M | 52.29M | -134.84M | -117.11M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-13 | Aggiornamento | Truist | Hold → Buy |
2024-12-10 | Reiterato | H.C. Wainwright | Buy |
2023-11-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
2022-06-13 | Ripresa | Wedbush | Neutral |
2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
2021-01-07 | Ripresa | Guggenheim | Neutral |
2021-01-06 | Iniziato | Stifel | Hold |
2020-12-16 | Ripresa | H.C. Wainwright | Buy |
2020-09-08 | Iniziato | BofA Securities | Buy |
2020-07-07 | Iniziato | SunTrust | Buy |
2019-08-26 | Iniziato | H.C. Wainwright | Buy |
2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
2018-10-10 | Iniziato | Guggenheim | Buy |
2018-06-20 | Iniziato | BofA/Merrill | Buy |
2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2017-06-22 | Ripresa | Jefferies | Buy |
2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
2015-12-04 | Iniziato | Wells Fargo | Outperform |
2015-10-23 | Ripresa | Jefferies | Buy |
2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
2010-07-29 | Reiterato | Wedbush | Outperform |
2009-10-19 | Iniziato | Brean Murray | Sell |
2009-10-07 | Reiterato | Leerink Swann | Outperform |
2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
How Sangamo Therapeutics Inc. stock reacts to bond yields2025 Earnings Surprises & Stepwise Trade Signal Guides - newser.com
Combining price and volume data for Sangamo Therapeutics Inc.Long Setup & Fast Gain Swing Trade Alerts - newser.com
Combining machine learning predictions for Sangamo Therapeutics Inc.Earnings Miss & Technical Entry and Exit Alerts - newser.com
What machine learning models say about Sangamo Therapeutics Inc.July 2025 Intraday Action & Precise Entry and Exit Recommendations - newser.com
Published on: 2025-10-12 23:29:27 - newser.com
Is Sangamo Therapeutics Inc. (GBY) stock a fit for income portfolios2025 Short Interest & Accurate Buy Signal Notifications - newser.com
Will earnings trigger a reversal in Sangamo Therapeutics Inc.Entry Point & Free Verified High Yield Trade Plans - newser.com
Sangamo Therapeutics (NASDAQ:SGMO) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Volume spikes in Sangamo Therapeutics Inc. stock – what they meanWeekly Investment Summary & Community Consensus Stock Picks - newser.com
What analysts say about Sangamo Therapeutics Inc stockAnalyst Upgrades & Compound Your Gains With Quality Stocks - earlytimes.in
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise - simplywall.st
Visual trend scoring systems applied to Sangamo Therapeutics Inc.Weekly Profit Summary & Step-by-Step Swing Trade Plans - newser.com
Published on: 2025-10-06 03:38:37 - newser.com
Why Sangamo Therapeutics Inc. (GBY) stock stays on buy listsEarnings Miss & Weekly Breakout Stock Alerts - newser.com
Is Sangamo Therapeutics Inc. (GBY) stock a good hedge against inflationWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Published on: 2025-10-05 05:08:49 - newser.com
What hedge fund activity signals for Sangamo Therapeutics Inc. stock2025 Price Targets & High Return Stock Watch Alerts - newser.com
Published on: 2025-10-05 02:36:48 - newser.com
Published on: 2025-10-03 07:10:00 - newser.com
How to monitor Sangamo Therapeutics Inc. with trend dashboards2025 Performance Recap & Fast Entry High Yield Tips - newser.com
Why Sangamo Therapeutics Inc. (GBY) stock stays resilientEarnings Miss & Expert Verified Movement Alerts - newser.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sangamo Biosciences CFO Resigns, New Officer Appointed - MSN
BRIEF-Sangamo Therapeutics Appoints Nikunj Jain As Principal Accounting Officer – SEC Filing - NewsX
Sangamo Therapeutics appoints Nikunj Jain as principal accounting officerSEC filing - MarketScreener
Sangamo Therapeutics, Inc. Appoints Nikunj Jain as Principal Accounting Officer, Effective October 1, 2025 - MarketScreener
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 28% - 富途牛牛
What analysts say about Tomra Systems ASA TMRA stockStochastic Oscillator Alerts & Target Triple-Digit Stock Opportunities - earlytimes.in
Published on: 2025-09-29 00:48:43 - newser.com
Published on: 2025-09-28 22:48:05 - newser.com
Can Olympia Industries Limited Maintain Its Share of Global Market for Its ProductBollinger Bands Signals & Exceptional Capital Growth - earlytimes.in
Goldman Sachs Group Inc. Sells 651,670 Shares of Sangamo Therapeutics, Inc. $SGMO - MarketBeat
The Escalator: Zealand Pharma, Area 23, Sangamo Therapeutics and more - Medical Marketing and Media
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In Growth - simplywall.st
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):